HAYWARD, Calif., Nov. 27 /PRNewswire/ -- Singulex Inc. today announced that it is collaborating with researchers at Wyeth Research to develop immunoassays on the company's Erenna(TM) system. Singulex has installed the Erenna system at Wyeth as part of its Erenna Technology Access Program (ETAP) and has begun optimizing assays that will allow Wyeth to accurately and precisely measure specific biomarkers in human blood.
"Biomarkers play an important role in the evaluation of compounds in both drug discovery and development, and we are keenly interested in applying new and improved technologies in the measurements of biomarkers," said Ole Vesterqvist, Ph.D., senior director of the Biomarker Laboratory in Clinical Translational Medicine at Wyeth. "For example, with the right biomarker and technology, one can study the effects of a therapeutic intervention in clinical studies. However, many biomarkers are present in human blood at extremely low concentrations, making it difficult to accurately and precisely measure. Singulex has provided us with a new technology for detection of biomarkers at very low concentrations and we are currently validating several assays in our laboratory that should help us guide our clinical programs."
Singulex's proprietary advanced biomarker detection technologies and optimized immunoassays are incorporated into Erenna, the company's flagship biomarker detection platform system. Erenna and accompanying assays are designed to measure very low levels and small changes of protein biomarkers across a variety of biological samples from multiple species. Singulex was the first to identify and quantify normal levels and small changes of cardiac troponin I, a protein biomarker used to detect cardiotoxicity and heart attacks, in human plasma.
"Singulex's technology extends the clinical utility of new and existing
biomarkers by removing the limits of detection," said Philippe Goix, Ph.D.,
president and CEO of Singulex. "The
|SOURCE Singulex Inc.|
Copyright©2007 PR Newswire.
All rights reserved